Adagene Inks Third Cancer Trial Collaboration With Merck

by Vandana Singh, Benzinga Editor

August 19, 2021 8:16 AM | 1 min read |

Adagene Inc ADAG has entered into a third clinical trial collaboration and supply agreement with Merck & Co Inc MRK.
The agreement includes an open-label, dose-escalation, and expansion clinical study of ADG106 combined with Merck's Keytruda (pembrolizumab) in advanced or metastatic solid and/or hematological malignancies.
ADG106 is a fully human ligand-blocking, agonistic anti-CD137 IgG4 mAb developed to treat advanced solid tumors and non-Hodgkin's lymphoma.
Related: Adagene To Test Its Anti-CTLA-4 Antibodies In Combination With Keytruda In Solid Tumors.
Price Action: ADAG shares closed 4.02% lower at $17.80 on Wednesday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.